1 / 24

Bones of Contention – HIV and Bone Disease Dr Paddy Mallon MB BCh BAO FRACP FRCPI PhD

Bones of Contention – HIV and Bone Disease Dr Paddy Mallon MB BCh BAO FRACP FRCPI PhD School of Medicine and Medical Sciences Mater Misericordiae University Hospital University College Dublin Ireland paddy.mallon@ucd.ie. UCD School of Medicine & Medical Science. Scoil an Leighis agus

lucian
Download Presentation

Bones of Contention – HIV and Bone Disease Dr Paddy Mallon MB BCh BAO FRACP FRCPI PhD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bones of Contention – HIV and Bone Disease Dr Paddy Mallon MB BCh BAO FRACP FRCPI PhD School of Medicine and Medical Sciences Mater Misericordiae University Hospital University College Dublin Ireland paddy.mallon@ucd.ie UCD School of Medicine & Medical Science Scoil an Leighis agus Eolaíocht An Leighis UCD

  2. What are the ‘bones of contention’? • Is low BMD more common in HIV? • Are fractures more common in HIV? • What’s the best measure – the ‘T’ score or the ‘Z’ score? • Is it ARV, BMI or vitamin D? • Which patients should I screen?

  3. What are the ‘bones of contention’? • Is low BMD more common in HIV? • Are fractures more common in HIV? • What’s the best measure – the ‘T’ score or the ‘Z’ score? • Is it ARV, BMI or vitamin D? • Which patients should I screen?

  4. Low BMD is common in HIV+ patients Adapted from Brown TT & Qaqish RB. AIDS 2006; 20:2165-2174

  5. Progression of BMD is common Spain. N=391. 49% osteopenic, 22% osteoporosis. Progression after 2.5 years: - 12.5% to osteopenia - 15.6% to osteoporosis Aquitaine cohort. N=255. 68% men. Age 44 yrs. All on ART. 72% osteopenic (osteoporosis excluded) Progression after 2.3 years: - 7.8% to osteopenia - 11.4% to osteoporosis Cazanave C et al. 17th CROI 2010. Abstract 747. Bonjoch A et al. 18th IAC 2010. Abstract THPDB104.

  6. What are the ‘bones of contention’? • Is low BMD more common in HIV? • Are fractures more common in HIV? • What’s the best measure – the ‘T’ score or the ‘Z’ score? • Is it ARV, BMI or vitamin D? • Which patients should I screen?

  7. Fractures are more common in HIV+ patients Healthcare Registry study 8,525 HIV-infected patients 2,208,792 non HIV-infected patients Fracture rates in women demonstrated HIV+ HIV- 7 6 Overall comparison p=0.002 5 4 Fracture prevalence in women /100 persons 3 2 1 0 40-49 70-79 50-59 60-69 30-39 Years Triant VA et al, JCEM 2008;93:3499-3504

  8. What are the ‘bones of contention’? • Is low BMD more common in HIV? • Are fractures more common in HIV? • What’s the best measure – the ‘T’ score or the ‘Z’ score? • Is it ARV, BMI or vitamin D? • Which patients should I screen?

  9. Osteoporosis / osteopenia T score = standard deviation (SD) difference from BMD of white women at peak bone density (aged 30 years)1,2 Z score = SD difference from BMD of individuals of the same age, race and gender 2 <50 yrs – Z score >50 yrs – T score 1. World Health Organ Tech Rep Ser 1994; 843:1–129 2. NIH consensus development panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001; 285:785–795

  10. What are the ‘bones of contention’? • Is low BMD more common in HIV? • Are fractures more common in HIV? • What’s the best measure – the ‘T’ score or the ‘Z’ score? • Is it ARV, BMI or vitamin D? • Which patients should I screen?

  11. # * # ART initiation is associated with bone loss Greater loss in BMD with ART containing NRTI -0.2 Within group and between-group differences all P<0.05 Lumbar spine Z score -0.3 ZDV/3TC/LPV/r NVP/LPV/r -0.4 -0.5 -0.6 -0.7 -0.8 -0.9 0 3 12 24 month • Changes in BMD accompanied by increases in markers of bone turnover von Voderen M. et al. AIDS 2009; 23(11): 1367-1376

  12. ART and bone Loss -ABC/3TC vs TDF/FTC Hip Lumbar Spine 0 0 P<0.001 P=0.036 -1  -1   % change in BMD - 2 - 2 % change in BMD    - 3 - 3   - 4 - 4 48 24 0 24 48 0 week week Subjects ABC/3TC: 176 134 117 182 141 125 TDF/FTC: 180 156 138 183 165 143 ABC/3TC: -1.90% TDF/FTC: -3.55% D = -1.68 ; 95% CI (-2.26, -1.09) ABC/3TC: -1.59% TDF/FTC: -2.41% D = -0.84 ; 95% CI (-1.61, -0.06) Stellbrink HJ et al., EACS 2009

  13. ART and bone loss - ABC/3TC vs TDF/FTC ACTG A5224s Hip Lumbar Spine McComsey GA et al. CROI 2010

  14. ART and bone loss - PI vs NNRTI Hip Lumbar Spine PI/ NNRTI PI/ NRTI NNRTI/ NRTI PI/ NNRTI PI/ NRTI NNRTI/ NRTI PI: LPV/r (40-74%) NNRTI: EFV (55-60%) NRTIs: AZT/3TC (85%) IDV/r (25-47%)NVP (37-45%) Duvivier, et al., AIDS 2009; 27:817-24

  15. ART and bone loss - PI vs NNRTI ACTG A5224s Hip Lumbar Spine McComsey GA et al. CROI 2010

  16. Body Mass Index and BMD…. • Consistently associated with low BMD in HIV1-7 • In one meta-analysis, low BMI explained much of the difference in BMD between HIV+ and HIV- 8 • Association between weight loss and BMD loss observed in HIV- male populations9 • Usually associated with negative health implications • Lower BMI in HIV+ patients associated with greater loss of BMD in prospective studies10 • Low BMI does not explain loss of BMD with ARV initiation 1. Mondy K, et al. CID 2003; 36:482–490 2. Fausto A et al.Bone 2006;38:893-7 3. Carr A et al. AIDS 2001;15:703-9 4. Nolan D et al. AIDS 2001;15:1275-80 5. Arnsten JH et al. AIDS 2007;21:617-23 6. Arnsten JH et al. CID 2006;42:1014-20 7. Dolan SE et al. JCEM 2006;91:2938-45 8. Bolland MJ et al. JCEM 2007;92:4522-8. 9. Shen Y et al. J Bone Mineral Res 2009;24:1290-1298. 10. Bonjoch A et al. 18th IAC 2010. Abstract THPDB104.

  17. Vitamin D….. • High prevalence of low vitamin D in HIV+ patients1-3 • High prevalence of low vitamin D in general population4 • Associations with EFV exposure and low 25-OH vitamin D (but not 1,25-OH vitamin D)2,5 • N=33. PHI. 45% osteopenia, 6% osteoporosis but none had vitamin D deficiency (25-OH and 1,25-OH)6 • Seasonal variation important4 • EFV use not associated with accelerated bone loss7 • High bone turnover state in HIV+ patients8 1. Jacobson D, et al. JAIDS 2008; 49:298–308, 2. Dao, CN et al, CROI 2010 #750. 3. 2. Fux et al. CROI 2010t #749. 4. Stephensen CB, et al. Am J Clin Nutr 2006; 83:1135–41. 5. Muller N. et al. CROI 2010 #752. 6. Grijsen ML et al. AIDS 2010;24 7. McComsey GA et al. CROI 2010. 8. Stellbrink HJ et al., EACS 2009

  18. Biomarkers and ART initiation… 97% 100 92% 81% 80% 75% 80 72% 60 ABC/3TC Unadjusted % change from baseline 44% 44% TDF/FTC 40 20 0 P1NP Osteocalcin BSAP CTX N= 114 134 112 130 114 134 113 134 In a multivariate analysis, differences between arms were statistically significant for P1NP, Osteocalcin and BSAP Stellbrink HJ et al., EACS 2009

  19. What are the ‘bones of contention’? • Is low BMD more common in HIV? • Are fractures more common in HIV? • What’s the best measure – the ‘T’ score or the ‘Z’ score? • Is it ARV, BMI or vitamin D? • Which patients should I screen?

  20. Who should be screened? EVERYBODY! >40 years old use FRAX (www.shef.ac.uk/FRAX) Or Consider DXA if ≥ 1 of following: History of low-impact fractures High falls risk Post-menopausal women Men >50 yrs Hypogonadism Steroid Exposure http://www.europeanaidsclinicalsociety.org/guidelines.asp

  21. BMD and the ‘Double Edged Sword’ ‘Main Entry: double–edged sword Function: noun Date: 15th century : something that has or can have both favorable and unfavorable consequences’

  22. Patient age in Brighton cohort: 1996-2009 HIV+ patients are getting older Personal communication, M. Fisher

  23. HIV+ patients are getting older Most of the age increase is in the 50-60 age group Patient age in Brighton cohort: 1996-2009 The increase in the over 50s is greater than the overall cohort Personal communication, M. Fisher

  24. Acknowledgements Grants / research support: Science Foundation Ireland, Molecular Medicine Ireland, European Union (NEAT), Irish Lung Foundation, Mater College, GlaxoSmithKline, Pfizer Speaker Bureau / Honoraria: GlaxoSmithKline, ViiV Healthcare, Merck, Gilead, Abbott, Tibotec, BMS

More Related